Show simple item record

dc.contributor.authorMATTHEWS, DNen_US
dc.contributor.authorGurgula, Oen_US
dc.contributor.editorBrett, Hen_US
dc.contributor.editorJones, Jen_US
dc.date.accessioned2016-07-26T10:04:25Z
dc.date.available2016-05-16en_US
dc.date.submitted2016-05-26T09:35:11.718Z
dc.identifier.issn1749-5083en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/13672
dc.description.abstractPotentially anti-competitive practices, such as reverse payment agreements and strategic patenting, risk allowing pharmaceutical companies to block the entry of generic and innovative medicines, stifling competition and harming consumers. Such practices create particular challenges for developing countries. Policy coherence between the IP system and competition law must be strengthened in order to promote innovation and access to health technologies.en_US
dc.format.extent661 - 667en_US
dc.languageEnglishen_US
dc.publisherSweet & Maxwellen_US
dc.relation.ispartofEuropean Intellectual Property Reviewen_US
dc.rightsTo be published in European Intellectual Property Review
dc.subjectcompetition lawen_US
dc.subjectaccess to medicinesen_US
dc.subjectreverse payment agreementsen_US
dc.subjectstrategic patentingen_US
dc.subjectpharmaceutical industryen_US
dc.subjectpatentsen_US
dc.subjectabuse of intellectual propertyen_US
dc.subjectpatent thicketsen_US
dc.subjectevergreeningen_US
dc.subjectproduct switchingen_US
dc.subjectdefensive patentingen_US
dc.titlePatent Strategies and Competition Law in the Pharmaceutical Sector: Implications for Access to Medicinesen_US
dc.typeArticle
pubs.issue11en_US
pubs.notes24 monthsen_US
pubs.publication-statusAccepteden_US
pubs.publisher-urlhttp://www.sweetandmaxwell.co.uk/Catalogue/ProductDetails.aspx?recordid=460en_US
pubs.volume38en_US
dcterms.dateAccepted2016-05-16en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record